In PDAC, activation of the oncogenic PI3K/AKT/mTOR signalling is linked to increased tumour growth, drug resistance and epithelial‐mesenchymal transition, weakened apoptosis and tumour immunogenicity, and worse pathological and clinical outcomes.44, 45, 46, 47, 48. The gene discussed is AKT1; the disease is neoplasm.